Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population.

e21133Background: Phase III studies conducted in Japanese (J-ALEX; JapicCTI-132316) and global (ALEX; NCT02075840) patients with treatment-naive ALK+ NSCLC demonstrated superiority of ALC 300 and 6...